Oxford BioMedica PLC (OXBDF)

[marcusl2]

These will hopefully be coming to OXB and they will not be last resort treatments. Big indications and this is when the numbers/royalties will really excite ;


CTL119 represents one of our latest advances in CAR-T cell therapy research and our broader commitment to pioneering breakthrough immuno-oncology treatments.
Said James Bradner, president of the Novartis Institutes for BioMedical Research

The underlying message: Novartis is planning to stay a leader long after CTL019 makes drug history.
(CLL), is the most common type of leukemia, generally considered incurable

CART-BCMA
Globally, multiple myeloma affected 488,000 people and resulted in 101,100 deaths in 2015
With high-dose therapy followed by autologous stem cell transplantation, the median survival has been estimated in 2003 to be approximately 4.5 years, compared to a median of approximately 3.5 years with "standard" therapy.[49] Overall the 5-year survival rate is around 35%

HTTPS://endpts.com/novartis-isnt-messing-around-with-car-t-and-it-has-a-next-gen-therapy-to-help-prove-it/